Drug Development

Milken Institute COVID-19 Response

Statement from Milken Institute Chairman Michael Milken All of us at Milken Institute are working closely with leaders in industry, government, and medical research organizations to: mitigate the spread of COVID-19; expedite the discovery...
Read Article
An older woman hugging a younger woman sitting against a couch

Changing the Story of Cancer: From Loss to Hope

Cancer is personal. Almost half of all men and a third of all women in the United States will receive a cancer diagnosis at some point in their lives. Yet this diagnosis still comes as a shock and sparks the fear of loss. I’ve certainly...
Read Essay
Image
A smiling light-skinned male with dark brown hair wearing glasses and a dark suit jacket over a light blue button-up shirt against a blurred background

Andy Schmeltz

Global President and General Manager, Pfizer Oncology

Hedging Pipeline Risk in Pharma: FDA Swaps and Annuities

The cost of capital to conduct medical R&D is high because investors must be compensated with significant returns to offset the risky and long drug-development process. This cost of capital could be reduced, and thus medical innovation...
Read Report
TP

Tomas J. Philipson

Formerly Milken Institute